Abstract
Background/Aims: Bezafibrate is naturally used for hyperlipidemia worldwide. In 1992 Day et al reported that the value of ALP and γ-GTP in hyperlipidemia declined aider administering bezafibrate orally. We conducted a study to investigate whether or not ALP and γ-GTP in primary biliary cirrhosis which is characterized by the elevation of these enzymes improved aider taking bezafibrate. Methodology: We administered bezafibrate additionally for 6 months to 13 patients with primary biliary cirrhosis (refractory PBC) whose liver enzymes (ALP or γ-GTP) did not renan within normal range out of 21 patients treated by monotherapy of ursodeoxycholic acid for 18 months. Results: At 2, 4, and 6 months, γ-GTP level significantly decreased compared with that prior to the initiation of bezafibrate. At and 6 months, ALP level significantly decreased compared with that prior to the initiation. At 2, 4 and 6 months, ALT level significantly decreased compared with that prior to the initiation. The value of IgG and IgM was also reduced significantly 6 months after the initiation. Conclusions: If the effectiveness of bezafibrate for primary biliary cirrhosis is confirmed histologically and by a randomized trial, a combination therapy of bezafibrate and ursodeoxycholic acid appear to be the medical treatment of choice for primary biliary cirrhosis in the future.
| Original language | English |
|---|---|
| Pages (from-to) | 1518-1521 |
| Number of pages | 4 |
| Journal | Hepato-Gastroenterology |
| Volume | 47 |
| Issue number | 36 |
| Publication status | Published - 2000 |
| Externally published | Yes |
Fingerprint
Keywords
- Bezafibrate
- PBC
ASJC Scopus subject areas
- Gastroenterology
Cite this
A novel treatment for refractory primary biliary cirrhosis? / Miyaguchi, S.; Ebinuma, H.; Imaeda, H.; Nitta, Y.; Watanabe, T.; Saito, Hidetsugu; Ishii, H.
In: Hepato-Gastroenterology, Vol. 47, No. 36, 2000, p. 1518-1521.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - A novel treatment for refractory primary biliary cirrhosis?
AU - Miyaguchi, S.
AU - Ebinuma, H.
AU - Imaeda, H.
AU - Nitta, Y.
AU - Watanabe, T.
AU - Saito, Hidetsugu
AU - Ishii, H.
PY - 2000
Y1 - 2000
N2 - Background/Aims: Bezafibrate is naturally used for hyperlipidemia worldwide. In 1992 Day et al reported that the value of ALP and γ-GTP in hyperlipidemia declined aider administering bezafibrate orally. We conducted a study to investigate whether or not ALP and γ-GTP in primary biliary cirrhosis which is characterized by the elevation of these enzymes improved aider taking bezafibrate. Methodology: We administered bezafibrate additionally for 6 months to 13 patients with primary biliary cirrhosis (refractory PBC) whose liver enzymes (ALP or γ-GTP) did not renan within normal range out of 21 patients treated by monotherapy of ursodeoxycholic acid for 18 months. Results: At 2, 4, and 6 months, γ-GTP level significantly decreased compared with that prior to the initiation of bezafibrate. At and 6 months, ALP level significantly decreased compared with that prior to the initiation. At 2, 4 and 6 months, ALT level significantly decreased compared with that prior to the initiation. The value of IgG and IgM was also reduced significantly 6 months after the initiation. Conclusions: If the effectiveness of bezafibrate for primary biliary cirrhosis is confirmed histologically and by a randomized trial, a combination therapy of bezafibrate and ursodeoxycholic acid appear to be the medical treatment of choice for primary biliary cirrhosis in the future.
AB - Background/Aims: Bezafibrate is naturally used for hyperlipidemia worldwide. In 1992 Day et al reported that the value of ALP and γ-GTP in hyperlipidemia declined aider administering bezafibrate orally. We conducted a study to investigate whether or not ALP and γ-GTP in primary biliary cirrhosis which is characterized by the elevation of these enzymes improved aider taking bezafibrate. Methodology: We administered bezafibrate additionally for 6 months to 13 patients with primary biliary cirrhosis (refractory PBC) whose liver enzymes (ALP or γ-GTP) did not renan within normal range out of 21 patients treated by monotherapy of ursodeoxycholic acid for 18 months. Results: At 2, 4, and 6 months, γ-GTP level significantly decreased compared with that prior to the initiation of bezafibrate. At and 6 months, ALP level significantly decreased compared with that prior to the initiation. At 2, 4 and 6 months, ALT level significantly decreased compared with that prior to the initiation. The value of IgG and IgM was also reduced significantly 6 months after the initiation. Conclusions: If the effectiveness of bezafibrate for primary biliary cirrhosis is confirmed histologically and by a randomized trial, a combination therapy of bezafibrate and ursodeoxycholic acid appear to be the medical treatment of choice for primary biliary cirrhosis in the future.
KW - Bezafibrate
KW - PBC
UR - http://www.scopus.com/inward/record.url?scp=0033636090&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0033636090&partnerID=8YFLogxK
M3 - Article
C2 - 11148991
AN - SCOPUS:0033636090
VL - 47
SP - 1518
EP - 1521
JO - Acta hepato-splenologica
JF - Acta hepato-splenologica
SN - 0172-6390
IS - 36
ER -